Cargando…
On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
The marketing and sale of oxycodone (OxyContin) by Purdue Pharma has commanded a great deal of legal and policy attention due to the drug’s central role in the ongoing overdose crisis. However, little is known about the basis for OxyContin’s approval by regulators, such as Health Canada in 1996. Tak...
Autores principales: | Pappin, Jessie, Bavli, Itai, Herder, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523806/ https://www.ncbi.nlm.nih.gov/pubmed/35924783 http://dx.doi.org/10.1177/17407745221108436 |
Ejemplares similares
-
Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin(®) Tablets Compared with Original OxyContin(®) Tablets in Healthy Adults
por: Perrino, Peter J., et al.
Publicado: (2013) -
OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
por: Fudin, Jeffrey, et al.
Publicado: (2016) -
The controversy surrounding OxyContin abuse: issues and solutions
por: Jayawant, Sujata S, et al.
Publicado: (2005) -
OxyContin and the McDonaldization of chronic pain therapy in the USA
por: Hughes, Jordan, et al.
Publicado: (2019) -
An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose
por: Beachler, Daniel C., et al.
Publicado: (2022)